/DBV.PA

DBV.PA Stock - DBV Technologies S.A.

Q: What is the analyst price target for DBV.PA?

Analyst price target information is not currently available for DBV.PA.

Q: What is DBV.PA's market cap?

Market capitalization information is not currently available for DBV.PA.

Healthcare|Biotechnology|PAR

$3.21-6.42%

$0.22 (-6.42%) • Dec 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $3.53

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for DBV.PA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.50

52W High$4.50

52W Low$0.61

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$4.15M	$15.73M	$4.80M	$5.71M	N/A
Gross Profit	$4.15M	$15.73M	$-15,499,259	$-3,565,415	$-18,817,631
Gross Margin	100.0%	100.0%	-322.9%	-62.5%	N/A
Operating Income	$-116,589,000	$-76,433,000	$-96,631,000	$-98,614,000	$-194,798,666
Net Income	$-113,918,000	$-72,726,000	$-96,300,000	$-97,809,000	$-195,677,971
Net Margin	-2744.4%	-462.4%	-2006.3%	-1713.5%	N/A
EPS	$-1.17	$-0.71	$-1.24	$-1.78	$-3.62

Company Overview

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Visit Website

Earnings History & Surprises

DBV.PA

Beat Rate

58%

Last 19 quarters

Avg Surprise

-85.1%

EPS vs Estimate

Beats / Misses

11/8

Last 12 quarters

Latest EPS

$-0.29

Q4 2025

EPS Surprise History

Q1 24

+64.7%

$-0.12vs$-0.33

Q2 24

+9.7%

$-0.28vs$-0.31

Q3 24

-70.0%

$-0.34vs$-0.20

Q4 24

+6.9%

$-0.32vs$-0.34

Q1 25

-470.4%

$-0.24vs$-0.04

Q2 25

+10.3%

$-0.26vs$-0.29

Q3 25

-744.0%

$-0.26vs$-0.03

Q4 25

-436.5%

$-0.29vs$-0.05

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 23, 2026	—	—	—	—
Q4 2025	Oct 28, 2025	$-0.05	$-0.29	-436.5%	✗ MISS
Q3 2025	Jul 29, 2025	$-0.03	$-0.26	-744.0%	✗ MISS
Q2 2025	Apr 30, 2025	$-0.29	$-0.26	+10.3%	✓ BEAT
Q1 2025	Mar 24, 2025	$-0.04	$-0.24	-470.4%	✗ MISS
Q4 2024	Nov 7, 2024	$-0.34	$-0.32	+6.9%	✓ BEAT
Q3 2024	Jul 31, 2024	$-0.20	$-0.34	-70.0%	✗ MISS
Q2 2024	May 8, 2024	$-0.31	$-0.28	+9.7%	✓ BEAT
Q1 2024	Mar 8, 2024	$-0.33	$-0.12	+64.7%	✓ BEAT
Q4 2023	Nov 1, 2023	$-0.28	$-0.16	+42.9%	✓ BEAT
Q3 2023	Aug 1, 2023	$-0.28	$-0.24	+14.3%	✓ BEAT
Q2 2023	May 5, 2023	$-0.26	$-0.20	+23.1%	✓ BEAT
Q1 2023	Mar 3, 2023	$-0.18	$-0.42	-132.2%	✗ MISS
Q4 2022	Nov 4, 2022	$-0.24	$-0.18	+25.0%	✓ BEAT
Q3 2022	Aug 2, 2022	$-0.27	$-0.35	-29.6%	✗ MISS
Q2 2022	May 3, 2022	$-0.43	$-0.30	+30.2%	✓ BEAT
Q1 2022	Mar 4, 2022	$-0.45	$-0.23	+48.9%	✓ BEAT
Q4 2021	Oct 27, 2021	$-0.35	$-0.37	-5.7%	✗ MISS
Q3 2021	Aug 3, 2021	$-0.49	$-0.56	-14.3%	✗ MISS
Q2 2021	May 3, 2021	$-0.50	$-0.45	+10.0%	✓ BEAT